WO2021017844A1 - 具有增强的抗湿疹功效的皮肤外用组合物 - Google Patents
具有增强的抗湿疹功效的皮肤外用组合物 Download PDFInfo
- Publication number
- WO2021017844A1 WO2021017844A1 PCT/CN2020/102293 CN2020102293W WO2021017844A1 WO 2021017844 A1 WO2021017844 A1 WO 2021017844A1 CN 2020102293 W CN2020102293 W CN 2020102293W WO 2021017844 A1 WO2021017844 A1 WO 2021017844A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skin
- eczema
- recipe
- external
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Definitions
- the present invention relates to a skin topical composition with enhanced anti-eczema effect, which comprises (A) concentrated birch tree juice with a concentration factor of about 1.05-8 times, preferably about 1.1-4 times, more preferably about 1.2- 2 times, and (B) selected from one of oatmeal extract, thorn fruit oil, calendula extract, allantoin, bisabolol, ceramide, panthenol, glycerin and squalane or Many substances.
- Eczema is an inflammatory skin disease with obvious exudative tendency caused by a variety of internal and external factors, accompanied by obvious itching, abnormal skin barrier function, and easy recurrence.
- oatmeal extract, calendula extract, allantoin, bisabolol, ceramide, panthenol, glycerin, squalane, squalane fruit oil and other ingredients in the cosmetics for eczema are such products. It is the most common anti-eczema and moisturizing ingredient, but the effect is not satisfactory in many cases.
- Birch is a deciduous tree of the birch family. There are currently about 100 species in the world, mainly distributed in the northern temperate zone and the cold temperate zone. Among them, there are about 29 varieties in my country, mainly distributed in the northeast, northwest, north and southwest. It has a great effect on preventing soil erosion, improving the environment, preventing wind and sand. Birch trees are mostly grown in remote mountainous areas with little human intervention and no industrial pollution. Birch sap is the fresh sap from the birch bark being cut or bored through the trunk. It is colorless or light yellow, free of precipitation and impurities, and has a light birch fragrance.
- the birch sap contains a lot of sugars, amino acids, vitamins, biotin, cytokinins, trace mineral elements, aromatic oils, betulin, saponin and other compounds. It has good moisturizing and anti-eczema functions.
- the present invention relates to (A) concentrated birch tree juice and (B) selected from oat kernel extract, thorn fruit oil, marigold flower extract, allantoin, bisabolol, ceramide, panthenol
- concentration of the concentrated birch tree juice is about 1.05-8 times, preferably About 1.1-4 times, more preferably about 1.2-2 times.
- the present invention relates to a skin external composition with enhanced anti-eczema effect, which comprises (A) concentrated birch tree sap with a concentration factor of about 1.05-8 times, preferably about 1.1-4 times, more Preferably about 1.2-2 times, and (B) is selected from oatmeal extract, thorn fruit oil, marigold extract, allantoin, bisabolol, ceramide, panthenol, glycerin and squalane Of one or more substances.
- the birch sap involved in the present invention is obtained from the genus Betula, Betula alba, Betula pubescens, Betula Pendula and Asian white birch (Betula platyphylla). Varieties.
- the birch sap is a colorless, transparent, no-sediment-free, and nutritious sap that is artificially collected by drilling holes in the base of the birch trunk between thawing and early spring.
- the birch sap is commercially available and used as it is, for example, it can be purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd.
- the concentrated birch sap in the present invention is obtained by concentrating the above-mentioned commercial products. Concentration methods are known in the art, such as heating concentration, low-temperature vacuum concentration, membrane concentration and the like. In the present invention, the concentration is preferably carried out by a low-temperature freeze concentration or membrane concentration process. For example, the commercially available birch juice stock solution is input into a low-temperature drying equipment, the temperature is lowered to -40°C to -70°C, and the vacuum is applied to 0.1-30Pa. Concentrated in vacuum at low temperature to obtain concentrated birch sap with different concentration times.
- controlling the concentration factor of birch sap is critical.
- controlling the concentration factor of birch sap is 1.05-8 times, preferably about 1.1-4 times, more preferably about 1.2-2 times.
- the present inventors found that the use of concentrated birch tree juice, oat kernel extract, thorn fruit oil, calendula extract, allantoin, bisabolol, ceramide, panthenol, glycerin, Compared with squalane, concentrated birch sap is combined with oat kernel extract, thorn fruit oil, calendula extract, allantoin, bisabolol, ceramide, panthenol, glycerin and/or squalane.
- Eczema has significantly better anti-eczema effect, which is much higher than the superposition effect of the two functions, which indicates that there is a synergistic effect between them.
- the content of the concentrated birch sap of the component (A) is about 18-98% by weight, preferably about 20-95% by weight, more preferably about 22-90% by weight, most preferably about 30-90% by weight, based on The total weight of the external skin composition.
- oatmeal extract In the component (B), oatmeal extract, thorn fruit oil, marigold extract, allantoin, bisabolol, ceramide, panthenol, glycerin and squalane are all known in the art. All known substances are commercially available.
- the content of the component (B) is about 0.01-10%, preferably 0.1-6, more preferably 0.5-5, based on the total weight of the skin external composition.
- the external skin composition includes a pharmaceutical composition or a cosmetic composition.
- the external skin composition does not contain any added water, but does not exclude the moisture inherently contained in each component.
- the external skin composition does not contain chelating agents such as EDTA salt, sodium polyphosphate, sodium metaphosphate, and gluconic acid.
- chelating agents such as EDTA salt, sodium polyphosphate, sodium metaphosphate, and gluconic acid.
- the skin external composition may optionally contain component (C) commonly used ingredients in skin external compositions, including but not limited to vehicles, active ingredients and Accessories etc.
- component (C) commonly used ingredients in skin external compositions, including but not limited to vehicles, active ingredients and Accessories etc.
- Component (C) is known in the art, and those skilled in the art can select its type and amount according to needs. For example, the total content of component (C) is usually about 2-80%, based on the skin external composition The total weight.
- the vehicle includes, for example, a diluent, a dispersant, or a carrier, and examples thereof include, but are not limited to, ethanol, dipropylene glycol, butylene glycol, and the like.
- the content of the vehicle in the skin topical composition is known in the art, for example, it usually accounts for 0.5-20% of the total weight of component (C).
- the active ingredients include, for example, emollients, moisturizers, anti-eczema active ingredients and the like.
- emollient examples include, but are not limited to, olive oil, macadamia nut oil, sweet almond oil, grape seed oil, avocado oil, corn oil, sesame oil, soybean oil, peanut oil, white flower seed oil, safflower seed oil, Dogtooth rose hip oil, argan argan oil, jojoba seed oil, sunflower seed oil, palm tree oil, ethylhexyl palmitate, isopropyl myristate, hydrogenated polyisobutylene, isohexadecane, isohexadecane Dodecane, diethylhexyl carbonate, dioctyl carbonate, isopropyl lauroyl sarcosine, isononyl isononanoate, hydrogenated polydecene, glycerol tri(ethylhexanoate), cetyl alcohol Ethylhexanoate, bis-diethoxydiethylene glycol cyclohexane 1,4-dica
- solid emollients include, but are not limited to, cetyl alcohol, stearyl alcohol, cetearyl alcohol, behenyl alcohol, scylitol, lauric acid, myristic acid, palmitic acid, stearic acid, beeswax, candelilla Tree wax, carnauba wax, lanolin, ozokerite, jojoba seed wax, paraffin wax, microcrystalline wax, hydrogenated rice bran wax, hydrogenated coconut oil glycerides, glyceryl behenate/eicosanate, myristyl alcohol One or more of myristate, bis-diglyceride polyacyl adipate-2, shea butter, and muluxing palm seed butter.
- the content of the emollient in the skin external composition is known in the art, for example, it usually accounts for 1-50% of the total weight of component (C).
- moisturizer examples include, but are not limited to, diglycerin, butylene glycol, propylene glycol, 1,3-propanediol, dipropylene glycol, 1,2-pentanediol, polyethylene glycol-8, polyethylene glycol- 32.
- anti-eczema active ingredients include, but are not limited to, dipotassium glycyrrhizinate, Portulaca oleracea (PORTULACA OLERACEA) extract, bio-carbohydrate gum-1, ⁇ -glucan, fructan, Scutellaria baicalensis (SCUTELLARIA BAICALENSIS) root extract Aesculus HIPPOCASTANUM extract, 4-tert-butylcyclohexanol, ceramide 3, Glycyrrhiza glabra (GLYCYRRHIZA GLABRA) extract, hydrolyzed royal jelly protein, oryzanol, sphingosine, quercetin (quercetin) Cortex), ginger root extract, rosemary leaf extract, etc.
- the content of the anti-eczema active ingredient in the skin external composition is known in the art, for example, it usually accounts for 0.01-10% of the total weight of component (C).
- the auxiliary materials include, for example, emulsifiers, thickeners, preservatives, perfumes and the like.
- emulsifier examples include, but are not limited to, cetearyl oleate, sorbitan oleate, polysorbate-60, polysorbate-80, methylglucose sesquistearic acid Ester, PEG-20 methyl glucose sesquistearate, PEG-40 hydrogenated castor oil, PPG-26-butanol-26, PEG-4 polyglycerol-2 stearate, PEG-60 hydrogenated Castor oil, steareth-2, steareth-21, PPG-13-decyltetradeceth-24, cetearyl glucoside, PEG-100 stearate, glycerin Stearate, Glyceryl Stearate SE, Coco Glucoside, Ceteareth-25, PEG-40 Stearate, Polyglyceryl-3 Methyl Glucose Distearate, Glyceryl stearate citrate, polyglyceryl-10 stearate, polyglyceryl-10 myristate, polyglyce
- the thickener examples include, but are not limited to, carbomers, acrylic acid (ester) and its derivatives, xanthan gum, gum arabic, polyethylene glycol-14M, polyethylene glycol-90M, succinyl poly One or more of high molecular polymers such as sugar, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.
- the content of the thickener in the external skin composition is known in the art, for example, it usually accounts for 0.1-10% of the total weight of the component (C).
- preservatives examples include, but are not limited to, methylparaben, propylparaben, phenoxyethanol, benzyl alcohol, phenethyl alcohol, bis(hydroxymethyl)imidazolidinylurea, potassium sorbate, sodium benzoate, chlorobenzene Glycerol, sodium dehydroacetate, caprylic hydroxamic acid, 1,2-hexanediol, 1,2-pentanediol, p-hydroxyacetophenone, caprylyl glycol, glyceryl caprylate, undecylenic acid
- the content of the preservative in the external skin composition is known in the art, for example, it usually accounts for 0.01-2% of the total weight of the component (C).
- the external skin composition with enhanced anti-eczema effect of the present invention can be prepared by any suitable method known in the art.
- it can be prepared by dissolving tanks, emulsifying pots, dispersers, and delivery pumps commonly used in the cosmetics field.
- the water-soluble substance into the water-phase dissolving kettle, and the oil-soluble substance into the oil-phase dissolving kettle, and heat the temperature of the two kettles to about 80°C.
- a disperser Pre-dispersion. After the dissolution is completed, the oil phase and the water phase are transported to the emulsifying pot for homogenization and emulsification for about 5-15 minutes. After the emulsification is completed, the temperature of the material body is reduced to normal temperature, optional flavors, preservatives, etc. are added, and the pH of the product is adjusted as necessary.
- the products can be filled and shipped only after the relevant
- the external skin composition can be made into various dosage forms such as creams, creams, emulsions, essences, sprays, and gels.
- Example 1 Gene expression related to moisture retention and barrier repair in different material systems
- This example investigated and studied the combination of oat kernel extract, marigold flower extract and birch sap on cutin transglutaminase TGM1, epidermal tight junction protein (ZO-1 and CLDN1), filaggrin FLG and water channel The influence of protein AQP3.
- the experimental method is as follows.
- Experimental reagents and consumables keratinocytes, 6-well plate, cell culture medium, RNA extraction kit, reverse transcription kit, Trizol lysis solution, etc.
- Inoculation Inoculate cells into a 6-well plate at a seeding density of 2E5/well, and incubate overnight in an incubator at 37°C and 5% CO 2 ;
- RNA is extracted, reverse transcribed to cDNA, and then subjected to fluorescence quantitative PCR detection;
- the 1.2 times, 4 times, and 9 times birch sap concentrates are obtained by concentrating the birch sap raw liquid.
- the concentration process is: the fresh white birch sap raw liquid purchased from Daxinganling Chaoyue Wild Berry Development Co., Ltd. is input into low-temperature drying Equipment, cool down to -65°C, vacuum to 0.1Pa, and concentrate to 1.2 times, 4 times and 9 times.
- Example 2 The effect of birch sap on the expression of proteins related to moisture retention and barrier repair
- This example investigated and studied the effects of allantoin, bisabolol and birch sap in combination on cutin transglutaminase TGM1, epidermal tight junction proteins (ZO-1 and CLDN1), filaggrin FLG and aquaporin AQP3 Expression influence.
- the experimental method is as follows.
- Experimental reagents and consumables human primary keratinocytes, 12-well plates, keratinocyte culture medium, ELISA test kits with different indicators, etc.
- Inoculation Inoculate in a 12-well culture plate at an inoculation density of 2E5/well, cultivate in an incubator at 37°C and 5% CO2, and change the medium every two days;
- Example 3 Effect of birch sap on the proliferation and differentiation of keratinocytes
- This example tested and compared the effects of ceramide, glycerol and birch sap in combination on the proliferation and differentiation of keratinocytes.
- the experimental method is as follows.
- HACAT human immortalized epidermal keratinocytes
- Experimental equipment and consumables 96-well plate, 1ml pipette, 5ml pipette, 1ml pipette tip, 5ml pipette tip, 15ml centrifuge tube, cell counter, 0.22um filter, row gun, row gun slot, DMEM cell culture solution , FBS, 100 ⁇ tertiary antibody, 100 ⁇ mycoplasma inhibitor, CCK-8 reagent.
- the above experiment is done in three groups in parallel.
- the cells come from three culture flasks, and cell counting and experimental operations are performed independently. The results obtained are shown in the following table:
- This example uses a zebrafish juvenile allergy model to test and compare the effects of panthenol, squalene and birch sap in combination on mast cell degranulation, thereby verifying the effect of birch sap in anti-eczema.
- the experimental method is as follows.
- the experimental procedure is as follows: Collect AB wild-type zebrafish embryos, culture them with E3 buffer in a 28.5°C incubator to 5dpf (days post fertilization), and change the medium every day. Randomly transfer 5 dpf zebrafish juveniles to a 48-well cell culture plate with 10 tails per well for grouping. Each group has 4 replicate wells.
- the grouping situation is as follows:
- a negative control group (without SP) is set up, with 4 multiple holes in each group; corresponding to the SP degranulation induction group and the negative control group without SP, a background control group ( No zebrafish juveniles), 2 replicate holes per group. Blot the remaining E3 buffer in each group of wells and add 250 ⁇ l of the solution corresponding to each group, and react for 60 minutes in a 28.5°C incubator in the dark. After 60 minutes, 200 ul of the supernatant of each group was placed in a 96-well cell culture plate, and the enzyme reaction substrate BAPNA was added to make the concentration reach 400 ⁇ g/ml.
- the 96-well plate was placed in a 28.5°C incubator for 2 hours in the dark and covered, and the light absorption value of the whole plate at 405nm was measured after 2 hours. The value reflects the release of tryptase from zebrafish mast cells.
- Example 5 The effect of birch sap on the production of inflammatory factors during eczema
- DNFB 2,4-dinitrofluorobenzene
- the experimental method is as follows.
- mice ICR mice, males.
- Experimental materials 0.5% DNFB acetone solution, depilatory cream, dust mite extract, birch sap, oat kernel extract, thorn fruit oil.
- the experimental procedure is as follows: ICR mice are randomly grouped according to their body weight, each with 12 mice, divided into normal group, model group, and sample group. In each group of experimental mice, one day before modeling, depilatory cream was used to remove skin and hair in an area of about 2x2cm on the back of the mice. To determine the scope of the experiment on the back of the mouse, the transparent wide tape was repeatedly pasted 8 times to remove the cuticle. Then in the first week, on the 1, 3, 5, and 7 days, all experimental animals were sensitized by injection of dust mite extract.
- the dust mite extract was injected to induce sensitization; in the 3rd to 6th week of the experiment, the dust mite extract was injected once a week to induce sensitization.
- Acetone (DNCB) should be diluted with double-distilled water to 0.5% acetone solution, and 0.5% DNCB was fixedly contacted on the back of the mouse every other day in the second week, as described above, once, 100 ⁇ L each time, and every other day from the second week. 70 ⁇ L each time, sensitized for 6 weeks.
- the medication was started 12 hours after the successful modeling, and birch sap of different concentrations was evenly sprayed on the back of the experimental mice with an aerosol bottle, 3 times a day for 7 consecutive days.
- the model group was sprayed with distilled water for 7 consecutive days, 3 times per day.
- the sample formula to be tested is as follows:
- the formula of the anti-eczema cream composition is as follows:
- the above anti-eczema cream composition is prepared as follows:
- the anti-eczema cream significantly improved the skin condition (p ⁇ 0.05), and further significantly improved on the 21st day (p ⁇ 0.01). This indicates that the anti-eczema cream can treat mild to moderate eczema.
- the formula of the anti-eczema essence composition is as follows:
- the aforementioned anti-eczema essence composition is prepared as follows:
- raw material 1 into the emulsifying pot, and sprinkle raw materials 14 and 15 into the emulsifying pot while stirring. After raw materials 14 and 15 are completely swelled, add raw materials 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and raw material 13, heat up to 80°C while stirring, homogenize at high speed for 5 minutes, and keep warm for 10 minutes;
- the anti-eczema essence significantly improved the skin condition (p ⁇ 0.05), and further significantly improved on the 21st day (p ⁇ 0.01). This indicates that the anti-eczema essence can treat mild to moderate eczema.
- Example 8 Anti-eczema emulsion composition
- the formula of the anti-eczema emulsion composition is as follows:
- the anti-eczema emulsion composition described above is prepared as follows:
- the anti-eczema emulsion significantly improved the skin condition (p ⁇ 0.05), and further significantly improved on the 21st day (p ⁇ 0.01). This indicates that the anti-eczema emulsion can treat mild to moderate eczema.
- the formula of the anti-eczema cream is as follows:
- the above anti-eczema cream is prepared as follows:
- the anti-eczema cream significantly improved the skin condition (p ⁇ 0.05), and further significantly improved on the 14th day (p ⁇ 0.01). This indicates that the anti-eczema cream can treat mild to moderate eczema.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
配方 | AQP3 | FLG | TGM1 | CLDN1 | ZO-1 |
配方1 | 9.14±0.163 | 9.321±0.149 | 16.28±0.199 | 16.5±0.39 | 9.81±0.198 |
配方2 | 8.98±0.245 | 8.97±0.311 | 15.98±0.275 | 16.2±0.541 | 9.21±0.211 |
配方3 | 7.22±0.143 | 7.36±0.129 | 10.83±0.21 | 12.21±0.18 | 6.76±0.118 |
配方4 | 4.218±0.116 | 4.62±0.139 | 4.518±0.171 | 5.915±0.587 | 2.496±0.154 |
配方5 | 4.678±0.196 | 4.71±0.289 | 4.978±0.261 | 6.318±0.647 | 2.896±0.314 |
配方6 | 4.461±0.188 | 3.991±0.159 | 4.794±0.222 | 6.29±0.948 | 2.601±0.164 |
配方7 | 2.01±0.12 | 1.56±0.211 | 1.99±0.256 | 2.89±0.291 | 1.245±0.511 |
配方8 | 1.71±0.22 | 1.46±0.191 | 1.79±0.196 | 2.49±0.561 | 1.005±0.341 |
配方9 | 4.055±0.232 | 3.35±0.121 | 4.32±0.132 | 5.01±0.93 | 2.153±0.294 |
配方10 | 8.62±0.103 | 8.57±0.259 | 13.98±0.235 | 14.9±1.29 | 8.11±0.278 |
配方11 | 5.12±0.143 | 5.36±0.149 | 9.73±0.21 | 8.71±0.58 | 3.86±0.198 |
配方12 | 3.945±0.192 | 3.13±0.101 | 4.12±0.19 | 4.85±0.33 | 1.953±0.114 |
成分(g) | 配方1 | 配方2 | 配方3 | 配方4 | 配方5 | 配方6 | 配方7 | 配方8 |
桦树汁原液 | 95 | 95 | 100 | |||||
1.2倍浓缩液 | 95 | 95 | 100 | |||||
尿囊素 | 5 | 5 | 5 | |||||
红没药醇 | 5 | 5 | 5 | |||||
水 | 95 | 95 |
样品 | TGM1 | ZO-1 | CLDN1 | FLG | AQP3 |
配方1 | 2.754±0.121 | 2.978±0.216 | 2.948±0.451 | 2.924±0.147 | 3.249±0.159 |
配方2 | 2.999±0.146 | 2.994±0.199 | 2.615±0.123 | 2.945±0.294 | 3.456±0.453 |
配方3 | 1.761±0.251 | 1.897±0.146 | 1.521±0.101 | 1.921±0.194 | 1.994±0.094 |
配方4 | 1.835±0.164 | 1.997±0.256 | 1.599±0.105 | 1.778±0.167 | 1.884±0.462 |
配方5 | 0.613±0.075 | 0.655±0.052 | 0.773±0.050 | 0.847±0.024 | 0.703±0.095 |
配方6 | 0.512±0.017 | 0.694±0.022 | 0.831±0.023 | 0.784±0.046 | 0.699±0.051 |
配方7 | 1.113±0.243 | 1.455±0.172 | 1.273±0.140 | 1.347±0.254 | 1.303±0.145 |
配方8 | 2.224±0.199 | 2.461±0.168 | 2.324±0.218 | 2.415±0.324 | 2.616±0.313 |
样品 | 细胞活力 |
配方1 | 168±1.41 |
配方2 | 171±3.14 |
配方3 | 152.3±1.51 |
配方4 | 140.3±1.32 |
配方5 | 145±3.21 |
配方6 | 141±1.64 |
配方7 | 106±2.18 |
配方8 | 110±1.98 |
配方9 | 130±2.23 |
配方10 | 151±3.55 |
配方11 | 145.3±1.31 |
配方12 | 135.1±2.34 |
成分(g) | 配方1 | 配方2 | 配方3 | 配方4 | 配方5 | 配方6 | 配方7 | 配方8 |
桦树汁原液 | 95 | 95 | 100 | |||||
1.2倍浓缩液 | 95 | 95 | 100 | |||||
泛醇 | 5 | 5 | 5 | |||||
角鲨烯 | 5 | 5 | 5 | |||||
水 | 95 | 95 |
组别 | 肥大细胞保护率 |
Model | - |
酮替芬 | 91.22% |
配方1 | 90.21% |
配方2 | 92.19% |
配方3 | 85.12% |
配方4 | 84.94% |
配方5 | 64.12% |
配方6 | 55.21% |
配方7 | 78.18% |
配方8 | 88.40% |
成分(g) | 配方1 | 配方2 | 配方3 | 配方4 | 配方5 | 配方6 | 配方7 | 配方8 |
桦树汁原液 | 95 | 95 | 100 | |||||
1.2倍浓缩液 | 95 | 95 | 100 | |||||
燕麦仁提取物 | 5 | 5 | 5 | |||||
青刺果油 | 5 | 5 | 5 | |||||
水 | 95 | 95 |
IL-4(pg/ml) | IL-13(pg/ml) | IL-17(pg/ml) | TSLP | |
模型组 | 58.9±0.32 | 36.21±1.27 | 61.39±1.46 | 89.79±1.27 |
正常组 | 21.61±0.46 | 12.97±2.44 | 34.21±2.19 | 40.61±1.99 |
配方1 | 26.94±2.94 | 14.61±0.49 | 38.94±3.44 | 35.91±2.22 |
配方2 | 27.25±1.24 | 15.11±2.44 | 39.19±2.22 | 44.21±2.91 |
配方3 | 28.33±3.21 | 18.22±1.54 | 34.59±2.21 | 45.31±3.21 |
配方4 | 31.89±2.99 | 18.86±0.71 | 39.21±1.44 | 46.21±1.22 |
配方5 | 49.13±1.88 | 38.24±1.29 | 48.94±1.29 | 66.21±5.21 |
配方6 | 52.11±1.07 | 41.22±3.14 | 53.21±3.22 | 69.21±6.11 |
配方7 | 35.29±2.03 | 22.76±2.89 | 45.23±3.56 | 51.24±3.56 |
配方8 | 32.25±1.24 | 18.59±2.31 | 42.51±1.25 | 48.91±1.61 |
序号 | 成分 | 重量% |
1 | 1.2倍浓缩桦树汁 | 76 |
2 | 水解透明质酸钠 | 0.05 |
3 | 金盏花提取物 | 4.05 |
4 | 黄原胶 | 0.1 |
5 | 羟苯甲酯 | 0.2 |
6 | 聚山梨醇酯-60 | 0.3 |
7 | PEG-60氢化蓖麻油 | 0.5 |
8 | 甜菜碱 | 1 |
9 | 双丙甘醇 | 4 |
10 | 神经酰胺 | 4 |
11 | 甘油 | 7.1 |
12 | 卡波姆 | 0.2 |
13 | 植物甾醇/辛基十二醇月桂酰谷氨酸酯 | 1 |
14 | 氨丁三醇 | 0.1 |
15 | PEG/PPG-17/6共聚物 | 1 |
16 | 苯氧乙醇 | 0.4 |
序号 | 成分 | 重量% |
1 | 1.2倍浓缩桦树汁 | 51.02 |
2 | 水解透明质酸钠 | 3.10 |
3 | 黄原胶 | 0.20 |
4 | 青刺果油 | 0.20 |
5 | 乙醇 | 4 |
6 | 泛醇 | 0.50 |
7 | 甜菜碱 | 3 |
8 | 甘油 | 10 |
9 | 白矿脂 | 5 |
10 | C12-15醇苯甲酸酯 | 5 |
11 | 液体石蜡 | 4 |
12 | 鲸蜡硬脂醇 | 3 |
13 | 硬脂酸 | 3 |
14 | 甘油硬脂酸酯/PEG-100硬脂酸酯 | 2.50 |
15 | 山梨坦硬脂酸酯 | 2 |
16 | 聚山梨醇酯-60 | 1 |
17 | 聚二甲基硅氧烷 | 2 |
18 | 苯氧乙醇 | 0.50 |
Claims (8)
- (A)浓缩的桦树汁与(B)选自燕麦仁提取物、青刺果油、金盏花提取物、尿囊素、红没药醇、神经酰胺、泛醇、甘油和角鲨烷中的一种或多种的组合在具有抗湿疹功效的皮肤外用组合物中的用途,其中所述浓缩的桦树汁的浓缩倍数为1.05-8倍,优选1.1-4倍,更优选1.2-2倍。
- 权利要求1的用途,其中所述皮肤外用组合物不包含任何外加的水。
- 权利要求1或2的用途,其中所述皮肤外用组合物是药物组合物或者化妆品组合物。
- 一种具有抗湿疹功效的皮肤外用组合物,其包含(A)浓缩的桦树汁,其浓缩倍数为1.05-8倍,优选1.1-4倍,更优选1.2-2倍,和(B)选自燕麦仁提取物、青刺果油、金盏花提取物、尿囊素、红没药醇、神经酰胺、泛醇、甘油和角鲨烷中的一种或多种物质。
- 权利要求4的皮肤外用组合物,其中所述组分(A)浓缩的桦树汁的含量为18-98%重量,优选20-95%重量,更优选22-90%重量,最优选30-90%重量,基于所述皮肤外用组合物的总重量。
- 权利要求4或5的皮肤外用组合物,所述组分(B)的含量为0.01-10%,优选0.1-6%,更优选0.5-5%,基于所述皮肤外用组合物的总重量。
- 权利要求4-6任一项的皮肤外用组合物,其中所述皮肤外用组合物不包含任何外加的水。
- 权利要求4-7任一项的皮肤外用组合物,其中所述皮肤外用组合物是药物组合物或者化妆品组合物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227006675A KR20220044974A (ko) | 2019-07-30 | 2020-07-16 | 항-습진 효과가 향상된 피부 외용 조성물 |
JP2022506230A JP7407269B2 (ja) | 2019-07-30 | 2020-07-16 | 強化された抗湿疹有効性を有する皮膚局所用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910697708.XA CN110732002A (zh) | 2019-07-30 | 2019-07-30 | 具有增强的抗湿疹功效的皮肤外用组合物 |
CN201910697708.X | 2019-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021017844A1 true WO2021017844A1 (zh) | 2021-02-04 |
Family
ID=69267778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/102293 WO2021017844A1 (zh) | 2019-07-30 | 2020-07-16 | 具有增强的抗湿疹功效的皮肤外用组合物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP7407269B2 (zh) |
KR (1) | KR20220044974A (zh) |
CN (1) | CN110732002A (zh) |
WO (1) | WO2021017844A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113081910A (zh) * | 2021-03-04 | 2021-07-09 | 优颜皮肤科学研究(广州)有限公司 | 一种修复组合物及其应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110732002A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗湿疹功效的皮肤外用组合物 |
CN110731974B (zh) * | 2019-07-30 | 2022-09-02 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗炎功效的皮肤外用组合物 |
CN111588655A (zh) * | 2020-06-09 | 2020-08-28 | 广州市轩颜化妆品有限公司 | 一种藻类皮肤屏障修护霜及其制备方法 |
CN114632136A (zh) * | 2020-12-15 | 2022-06-17 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗湿疹功效的皮肤外用组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2120272C1 (ru) * | 1996-02-16 | 1998-10-20 | Товарищество с ограниченной ответственностью "Биокосметическая фабрика" | Зимний косметический крем для защиты кожи |
CN110732002A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗湿疹功效的皮肤外用组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008074796A (ja) * | 2006-09-22 | 2008-04-03 | Just World Inc | 抗糖尿病食品 |
CN108670878B (zh) * | 2018-08-01 | 2021-06-04 | 养生堂(安吉)化妆品有限公司 | 抗皮肤过敏的化妆品组合物 |
-
2019
- 2019-07-30 CN CN201910697708.XA patent/CN110732002A/zh active Pending
-
2020
- 2020-07-16 WO PCT/CN2020/102293 patent/WO2021017844A1/zh active Application Filing
- 2020-07-16 JP JP2022506230A patent/JP7407269B2/ja active Active
- 2020-07-16 KR KR1020227006675A patent/KR20220044974A/ko active Search and Examination
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2120272C1 (ru) * | 1996-02-16 | 1998-10-20 | Товарищество с ограниченной ответственностью "Биокосметическая фабрика" | Зимний косметический крем для защиты кожи |
CN110732002A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗湿疹功效的皮肤外用组合物 |
Non-Patent Citations (11)
Title |
---|
"Local Food Safety Standards: Silver Birch (Betula Pendula) Sap Concentrate", LOCAL STANDARDS IN HEILONGJIANG, vol. DS23, 19 December 2018 (2018-12-19), pages 1 - 8, XP009525688 * |
CAO, XI ET AL: "Study on Acute Toxicity Test and Skin Irritation Test of Dermatitis Gel containing Prinsepia Utilis Seed Oil", YUNNAN JOURNAL OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA, vol. 37, no. 5, 31 December 2016 (2016-12-31), pages 52 - 53, XP009525724, DOI: 10.16254/j.cnki.53-1120/r.2016.05.027 * |
CHEN, XU ET AL: "Eczema Diagnosis and Treatment", CHINESE JOURNAL OF GENERAL PRACTITIONERS, vol. 9, no. 2, 28 February 2010 (2010-02-28), pages 140 - 141, XP009525725, ISSN: 1671-7368 * |
HUANG MIAOLING , WANG DONGMEI , MEI JIAQI , YANG DEPO: "Chemical Composition of the Volatile Oil and the Immersion Oil of Calendula Officinalis L. and Its Application in Aromatherapy", THE 7TH PROCEEDINGS OF THE SEMINAR ON FRAGRANCE AND FLAVOR CHINA, 1 May 2008 (2008-05-01), pages 97 - 102, XP055776283 * |
JIANG, ZHONGHAI: "Study on the Birch Juice in Heilongjiang", SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, vol. 23, no. 10, 31 October 2002 (2002-10-31), pages 62 - 63, XP009525685, DOI: 10.13386/j.issn1002-0306.2002.10.024 * |
LYU, YAOCHANG ET AL: " Development and Uses of Oats for Its Health Benefits", FARM PRODUCTS PROCESSING, no. 3, 31 March 2011 (2011-03-31), pages 8 - 9, XP009525728, ISSN: 1671-9646 * |
SHENG, YAN ET AL: "Research Progress in Nutrient Composition Function and Utilization of Birch Sap", FARM PRODUCTS PROCESSING, no. 7, 31 July 2017 (2017-07-31), pages 49 - 52, XP055776281, ISSN: 1671-9646, DOI: 10.16693/j.cnki.1671-9646 * |
SONG, GUO'AI: "Vitamins and Cosmetics", PROCEEDINGS OF THE SEMINAR ON COSMETICS CHINA 2002, 31 March 2002 (2002-03-31), pages 255 - 259, XP009525729 * |
WAN WEN-TING, SONG YAN-JUN, XU LI-JIA, XIAO ,PEI-GEN, JIAN-HUA MIAO: "An Overview on Modern Research and Application potency of Chamomile", MODERN CHINESE MEDICINE, vol. 21, no. 2, 20 February 2019 (2019-02-20), pages 260 - 265, XP055776285, ISSN: 1673-4890, DOI: 10.13313/j.issn.1673-4890.20181008002 * |
WANG HE-CONG , HE CONG-FEN: "Research and Application Status of Ceramide in Skin", CHINA SURFACTANT DETERGENT & COSMETICS, vol. 49, no. 1, 22 January 2019 (2019-01-22), pages 51 - 57, XP055776287, ISSN: 1001-1803, DOI: 10.3969/j.issn.1001-1803.2019.01.011 * |
ZULING JIANG, QIANQIAN TANG, AN HUANG, JIANHUI WANG: "Research Progress in External Therapy for Chronic Eczema", MEDICAL RECAPITULATE, vol. 24, no. 20, 18 October 2018 (2018-10-18), pages 4103 - 4107, XP055776282, ISSN: 1006-2084, DOI: 10.3969/j.issn.1006-2084.2018.20.027 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113081910A (zh) * | 2021-03-04 | 2021-07-09 | 优颜皮肤科学研究(广州)有限公司 | 一种修复组合物及其应用 |
CN113081910B (zh) * | 2021-03-04 | 2023-08-25 | 优颜皮肤科学研究(广州)有限公司 | 一种修复组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110732002A (zh) | 2020-01-31 |
JP2022542404A (ja) | 2022-10-03 |
KR20220044974A (ko) | 2022-04-12 |
JP7407269B2 (ja) | 2023-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021017838A1 (zh) | 具有抗湿疹功效的皮肤外用组合物 | |
WO2021017844A1 (zh) | 具有增强的抗湿疹功效的皮肤外用组合物 | |
JP7320666B2 (ja) | 強化された抗炎症有効性を有する皮膚局所用組成物 | |
WO2021017846A1 (zh) | 增强的抗衰老化妆品组合物 | |
WO2021017833A1 (zh) | 抗衰老化妆品组合物 | |
WO2021017835A1 (zh) | 增强的美白化妆品组合物 | |
CN108670878B (zh) | 抗皮肤过敏的化妆品组合物 | |
WO2021017913A1 (zh) | 增强的保湿化妆品组合物 | |
WO2021017834A1 (zh) | 具有抗炎功效的皮肤外用组合物 | |
CN112118856A (zh) | 包含积雪草选择三萜的局部用护肤组合物 | |
CN114632049B (zh) | 一种防脱生发组合物 | |
JP2003292432A (ja) | 皮膚外用剤 | |
CN112656731A (zh) | 一种具有修红功效的组合物及其制备方法和应用 | |
JPH05163135A (ja) | 美白用化粧料組成物 | |
CN114948814B (zh) | 紫珠果提取物在制备抑制组胺生成的护肤品中的应用 | |
JP3107254B2 (ja) | 色白化粧料 | |
JP6416433B1 (ja) | 皮膚外用剤 | |
WO2021017448A1 (zh) | 具有止痒功效的皮肤外用组合物 | |
JP2009084212A (ja) | インボルクリン産生促進剤 | |
CN112842976B (zh) | 酵母菌发酵的桦树汁及其在抗炎化妆品组合物中的应用 | |
CN114632136A (zh) | 具有增强的抗湿疹功效的皮肤外用组合物 | |
JPH05124950A (ja) | 美白用化粧料組成物 | |
JP3822517B2 (ja) | 皮膚外用剤 | |
CN113876669B (zh) | 一种抗糖化中药组合物及其制备方法和在美容产品中的应用 | |
CN114983875A (zh) | 一种舒敏抗炎护肤组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20846852 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022506230 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20227006675 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20846852 Country of ref document: EP Kind code of ref document: A1 |